May 14 (Reuters) - Merck & Co Inc MRK.N:
FDA APPROVES MERCK’S WELIREG® (BELZUTIFAN) FOR THE TREATMENT OF ADULTS AND PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH LOCALLY ADVANCED, UNRESECTABLE, OR METASTATIC PHEOCHROMOCYTOMA OR PARAGANGLIOMA (PPGL)
MERCK & CO INC: WELIREG LABEL CONTAINS A BOXED WARNING THAT EXPOSURE TO WELIREG DURING PREGNANCY CAN CAUSE EMBRYO-FETAL HARM